Iron Status and Hypoxic Pulmonary Vascular Responses

University of Oxford

Status: Completed

Conditions: Iron Deficiency; Lung Hypoxia; Pulmonary Arterial Hypertension

Treatments: Other: Subacute hypoxic exposures; Drug: Intravenous administration of ferric carboxymaltose

Study type: Interventional

Funder types: Other

Identifiers

NCT01847352

12/SC/0710

Details and patient eligibility

About

On exposure to hypoxia (low oxygen) the normal response is for pulmonary arterial systolic blood pressure (PASP, blood pressure through the lungs) to increase. We have previously shown that raising iron by giving an infusion of iron into a vein reduces this pressure rise and that lowering iron by giving a drug that binds iron, magnifies this response. This is potentially a clinically important observation since iron-deficient people may be at increased risk of pulmonary hypertension if exposed transiently or permanently to hypoxia due to lung disease or residence at high altitude; furthermore if this were true then intravenous iron could be an important treatment in this patient group in the event of hypoxic exposure. The observed effects of iron on PASP are likely to be because iron levels affect oxygen sensing. Low iron levels make the body behave as if exposed to low oxygen by inhibiting the breakdown of the family of oxygen-sensing transcription factors, 'hypoxia inducible factor' or HIF. This includes one of the body's normal responses to low oxygen levels - raising blood pressure through the lungs.

This study will answer the question (1) do iron-deficient volunteers have a greater rise in PASP with hypoxia than those who are iron-replete, and (2) does giving intravenous iron cause a greater reduction in the rise in PASP in those who are iron-deficient than iron-replete? The purpose of this study is not to test the safety or clinical efficacy of iron which is already known.

Enrollment: 31 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Willing and able to give informed consent for participation in the study
• Men and women aged 18 years or older and generally in good health
• Detectable tricuspid regurgitation on echocardiography during both normoxia and hypoxia enabling measurement of pulmonary arterial pressure
• For iron-deficient volunteers: ferritin ≤15microg/L and transferrin saturation <16%
• For iron-replete volunteers: ferritin ≥20microg/L and transferrin saturation ≥20%

Exclusion criteria

• Haemoglobin <8.0g/dl
• Haemoglobinopathy
• Iron overload defined as ferritin >300microg/L
• Hypoxia at rest or on walking (SaO2 <94%) or significant comorbidity that may affect haematinics, pulmonary vascular or ventilatory responses, e.g. current infection, a chronic inflammatory condition, known cardiovalvular lesion or pulmonary hypertension, uncontrolled asthma or chronic obstructive pulmonary disease
• Exposure to high altitude (>2,500m) within the previous six weeks or air travel >4 hours within the previous week
• Iron supplementation or blood transfusion within the previous 6 weeks
• Pregnancy or breast feeding

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

31 participants in 2 patient groups

Iron-deficient

Other group

Description:

Healthy volunteers meeting iron-deficient entry criteria; Intravenous administration of ferric carboxymaltose; Subacute hypoxic exposures

Treatment:

Drug: Intravenous administration of ferric carboxymaltose

Other: Subacute hypoxic exposures

Iron-replete

Other group

Description:

Healthy volunteers meeting iron-replete entry criteria; Intravenous administration of ferric carboxymaltose; Subacute hypoxic exposures

Treatment:

Drug: Intravenous administration of ferric carboxymaltose

Other: Subacute hypoxic exposures